Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Cancer. 2019 Sep 15;125(18):3121-3130. doi: 10.1002/cncr.32354. Epub 2019 Jul 10.
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics. Such patients with MRD have a high risk of disease recurrence over a short timeframe, but optimal treatment strategies are unknown. Outcomes with conventional treatment, including allogeneic hematopoietic cell transplantation, are worse than those for patients without MRD. Herein, the authors review current strategies, including novel clinical trials, targeted toward patients with MRD.
患有急性髓系白血病（AML）并达到形态学完全缓解的患者仍可通过多参数流式细胞术、分子方法或细胞遗传学检测到可测量的残留疾病（MRD）。此类具有 MRD 的患者在短时间内疾病复发的风险很高，但最佳治疗策略尚不清楚。包括异基因造血细胞移植在内的常规治疗的结果比无 MRD 的患者差。在此，作者综述了针对 MRD 患者的当前策略，包括新的临床试验。
